Talkin Immunology with BioLegend

Antibody Therapies in Cancer

June 4, 2015
Description: Antibody therapies have become incredibly popular for the treatment of diseases, including cancer. In cancer, it may be beneficial to prevent interaction of “immune checkpoints”, which can inactivate T cells. Learn more with our podcast about some of the more popular antibody and nanobody treatments.

KEYTRUDA®, an anti-PD-1 therapy
Merck antibody therapy results for cancer studies
Amgen antibody therapy results
Melanoma antibody therapy for PD-1 approved in EU
The development of therapeutic antibodies
Advancements in the development of therapeutic monoclonal antibodies
Monoclonal antibody therapy

Keywords: cancer, tumor, antibody therapy, therapeutics, immune checkpoints, PD1, PDL1, LAG3, TIM3, CD80, CD86, Galectin 9, MHC II, CTLA4, Pembrolizumab, Ipilimumab, Nivolumab, nanobody, melanoma, carcinoma, biolegend, science, podcast, merck, amgen